Stock

Bicycle Therapeutics plc BCYC

$3.91-6.35%

All stocks Create account to unlock

Overview

BCYC market data

Price History

BCYC price chart

Valuation & Profitability

no valuation data

No Valuation Data Yet

Alpha Vantage and Twelve Data both returned no valuation metrics for BCYC. Check back after the next daily valuation refresh — this symbol may be new, delisted, or temporarily unavailable from both providers.

Company news

2 captured

Bicycle Therapeutics' Zelenectide Pevedotin Plus Pembrolizumab Shows SOC-Comparable Response And Improved Safety Profile In Metastatic Urothelial Cancer Phase 2 Study · May 21, 2026, 9:15 PM

8-K filing — BICYCLE THERAPEUTICS PLC (BCYC) · May 21, 2026, 9:05 PM

Decision & Score

Members

Our Tradable / Watch / Avoid decision and 0–100 conviction score for this symbol are members-only.

Create account to unlock

Trend & Pattern Evidence

Members

Trend alignment and backtested chart-pattern probabilities are members-only.

Create account to unlock

Sector Peer Ranking

Members

Ranked sector peers with scores and decisions are members-only.

Create account to unlock